Literature DB >> 22220854

p53 protein expression in chronic lymphocytic leukemia.

Ludger Sellmann1, Alexander Carpinteiro, Holger Nückel, René Scholtysik, Dörte Siemer, Ludger Klein-Hipass, Dieter Kube, Jan Dürig, Ulrich Dührsen, Jens Stanelle, Ralf Küppers.   

Abstract

Alterations in the function of the p53 pathway are frequently described in chronic lymphocytic leukemia (CLL), mostly associated with deletion of 17p13 and/or mutations of the TP53 gene. In the present study, we investigated 103 CLLs for the impact of protein expression of full-length p53 and its isoforms β and γ. A strong correlation between deletions of 17p13 and an accumulation of full-length p53 protein was found and was associated with a worse outcome compared to CLL with normal p53 (treatment-free survival p < 0.001, overall survival p = 0.04). Interestingly, the relative expression levels between full-length p53 protein and its isoforms β and γ were significantly altered in CLL even without deletions of 17p13, compared to normal B-cells (p = 0.005). Furthermore, CLLs with higher p53 protein ratios showed worse clinical courses compared to CLLs with lower p53 protein ratios. Taken together, the differential expression of p53 isoforms could disrupt the p53 response and contribute to CLL pathogenesis.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22220854     DOI: 10.3109/10428194.2011.654115

Source DB:  PubMed          Journal:  Leuk Lymphoma        ISSN: 1026-8022


  2 in total

1.  Subnetwork-based analysis of chronic lymphocytic leukemia identifies pathways that associate with disease progression.

Authors:  Han-Yu Chuang; Laura Rassenti; Michelle Salcedo; Kate Licon; Alexander Kohlmann; Torsten Haferlach; Robin Foà; Trey Ideker; Thomas J Kipps
Journal:  Blood       Date:  2012-07-26       Impact factor: 22.113

2.  Expression of TP53 isoforms p53β or p53γ enhances chemosensitivity in TP53(null) cell lines.

Authors:  Elisabeth Silden; Sigrun M Hjelle; Line Wergeland; André Sulen; Vibeke Andresen; Jean-Christophe Bourdon; David R Micklem; Emmet McCormack; Bjørn Tore Gjertsen
Journal:  PLoS One       Date:  2013-02-11       Impact factor: 3.240

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.